Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Has Consensus Target Price of $30.14

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $31.61.

Several equities research analysts have issued reports on the stock. Oppenheimer initiated coverage on shares of Pacira BioSciences in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $32.00 price objective for the company. Leerink Partners initiated coverage on shares of Pacira BioSciences in a research note on Wednesday, September 9th. They issued a “market perform” rating and a $28.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Pacira BioSciences in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Finally, Weiss Ratings cut shares of Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, September 16th.

Insider Activity at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the sale, the insider owned 216,384 shares in the company, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Pacira BioSciences

Large investors have recently bought and sold shares of the company. Wedge Capital Management L L P NC purchased a new position in Pacira BioSciences in the 2nd quarter valued at about $2,399,000. Rice Hall James & Associates LLC purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $2,369,000. Bank of New York Mellon Corp purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $7,532,000. Gagnon Advisors LLC lifted its stake in shares of Pacira BioSciences by 22.3% in the fourth quarter. Gagnon Advisors LLC now owns 260,908 shares of the company’s stock worth $6,752,000 after acquiring an additional 47,506 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of Pacira BioSciences by 31.0% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 203,520 shares of the company’s stock worth $5,163,000 after acquiring an additional 48,124 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences News Summary

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris to acquire Pacira for $36.50 per share: Viatris Inc. (NASDAQ: VTRS) agreed to purchase all outstanding Pacira shares for $36.50 in cash, valuing the equity at approximately $1.65 billion. The transaction is expected to close by the end of 2026, subject to customary conditions and approvals. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Strategic value supports the premium: Viatris plans to add Pacira’s marketed, patent-protected non-opioid pain medicines EXPAREL and ZILRETTA to its portfolio, expand their international reach, and pursue commercial and research synergies. Viatris expects the acquisition to be immediately accretive to its financial guidance metrics. Viatris Agrees to Acquire Pacira BioSciences in a $1.65 Billion Deal

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock opened at $36.39 on Tuesday. Pacira BioSciences has a twelve month low of $18.80 and a twelve month high of $36.46. The stock has a market capitalization of $1.45 billion, a P/E ratio of 103.97 and a beta of 0.25. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. The business’s fifty day moving average price is $25.37 and its 200 day moving average price is $24.51.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.65 by $0.08. The company had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 earnings per share. As a group, research analysts anticipate that Pacira BioSciences will post 1.91 earnings per share for the current year.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.